List view / Grid view
The East Syracuse site will serve as the LOTTE Centre for North America Operations for LOTTE’s new biologics contract development and manufacturing organisation (CDMO) business in the United States.
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide (CGRP) programmes, including migraine treatment rimegepant.
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
It seems that sprinkles, commonly known as hundreds and thousands, have undersold their capabilities, as a US scientist identifies their application could uniquely identify billions of individual tablets, potentially thwarting industry fraud.
Novartis has suspended production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey as it addresses potential quality issues identified in its manufacturing processes.
The International Society for Pharmaceutical Engineering (ISPE) has published the Good Practice Guide: Continuous Manufacturing of Oral Solid Dosage Forms, in a bid to increase uptake.
Winners of ISPE's Facility of the Year Awards (FOYA) 2022 include Janssen, Takeda, CRISPR Therapeutics, Catalent and Iovance Biotherapeutics.
Following a successful pilot in 2021, Sanofi and McLaren Racing have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines, across all technologies.
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
A recent empirical study of continuous manufacturing (CM) versus batch processing of US and non‑US pharmaceutical manufacturing facilities suggests that CM would be more economical than batch facilities, at least for the production of oral solid dosage products. This has significant consequences for policies and strategies to reduce supply chain…
Leakage, cracking and corrosion in pressure vessels present a serious risk for operators of pharmaceutical production systems. Imminent damage must be reliably identified at an early stage to enable necessary steps to be promptly taken. Oliver Großgart, Plant Safety Expert at TÜV SÜD Industrie Service GmbH, explains how TÜV SÜD…
The new chemical reaction, a carbon-hydrogen amination cross-coupling reaction, creates a faster, simpler way of making tertiary amines without the inherent limitations of classic methods.
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…
